Home/Shanton Pharma/Pieter de Ridder, MBA

PD

Pieter de Ridder, MBA

VP of Business Development

Therapeutic Areas

Gout Hyperuricemia Pruritus

Shanton Pharma Pipeline

Drug	Indication	Phase
SAP-001	Refractory/Tophaceous Gout	Phase 2

Leadership Team at Shanton Pharma

Chief Executive Officer

Wenfeng Miao, M.D., Ph.D.

Chief Medical Officer

Shanshan Cui, Ph.D.

VP of Clinical Development

Carmen Arencibia

Director of Clinical Operations

View full Shanton Pharma profile